Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia.

Abstract

BACKGROUND:

In non-dialysis chronic kidney disease (CKD) patients with dyslipidemia, statin therapy is recommended to prevent cardiovascular complications. Dyslipidemia has been also shown to be an independent risk factor for the progression of CKD. However, it is still unclear whether statin therapy exerts an inhibitory effect on renal deterioration in CKD patients with dyslipidemia. The purpose of the present study was to examine possible therapeutic effects of statin add-on therapy on renal function as well as parameters of lipid and glucose metabolism, arterial stiffness and oxidative stress, in comparison to diet therapy, in CKD patients with dyslipidemia.

METHODS:

This study was a randomized, open-label, and parallel-group trial consisted of a 12-months treatment period in non-dialysis CKD patients with alubuminuria and dyslipidemia. Twenty eight patients were randomly assigned either to receive diet counseling alone (diet therapy group) or diet counseling plus pitavastatin (diet-plus-statin therapy group), to achieve the LDL-cholesterol (LDL-C) target of <100 mg/dl.

RESULTS:

The statin treatment by pitavastatin was well tolerated in all of the patients without any significant adverse events and the average dose of pitavastatin was 1.0 ± 0.0 mg daily after treatment. After the 12-months treatment period, LDL-C was significantly lower in the diet-plus-statin therapy group compared with the diet therapy group (diet vs diet-plus-statin: LDL-C, 126 ± 5 vs 83 ± 4 mg/dL, P < 0.001). On the other hand, the diet-plus-statin therapy did not significantly reduce albuminuria or delay the decline in eGFR compared with the diet therapy, and there was no relationship between the change in LDL-C and the change in eGFR or albuminuria. However, diet therapy as well as diet-plus-statin therapy exerted similar lowering effects on the pentosidine levels (diet therapy group, baseline vs 12 months: 40 ± 4 vs 24 ± 3 ng/mL, P = 0.001; diet-plus-statin therapy, 46 ± 7 vs 34 ± 6 ng/mL, P = 0.008). Furthermore, the results of multivariate regression analysis indicated that the change in pentosidine was a significant contributor to the change in eGFR (β = -0.536, P = 0.011).

CONCLUSIONS:

Although statin add-on therapy did not show additive renal protective effects, the diet therapy as well as the diet-plus-statin therapy could contribute to the reduction in plasma pentosidine in CKD patients with albuminuria and dyslipidemia.

• Authors: Masato Ohsawa, Kouichi Tamura, Hiromichi Wakui, Tomohiko Kanaoka, Kengo Azushima, Kazushi Uneda, Sona Haku, Ryu Kobayashi, Kohji Ohki, Kotaro Haruhara, Sho Kinguchi, Yoshiyuki Toya, Satoshi Umemura
• Journal: Lipids in health and disease (Lipids Health Dis) Vol. 14 Pg. 161 (Dec 09 2015) ISSN: 1476-511X [Electronic] England
• PMID: 26645467 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anticholesteremic Agents
• Cholesterol, HDL
• Cholesterol, LDL
• Glycation End Products, Advanced
• Quinolines
• Triglycerides
• Arginine
• pentosidine
• Lysine
• pitavastatin

Topics

• Aged
• Albuminuria (blood, diet therapy, drug therapy, pathology)
• Anticholesteremic Agents (therapeutic use)
• Arginine (analogs & derivatives, antagonists & inhibitors, blood)
• Cholesterol, HDL (blood)
• Cholesterol, LDL (antagonists & inhibitors, blood)
• Diet (methods)
• Dyslipidemias (blood, diet therapy, drug therapy, pathology)
• Female
• Glomerular Filtration Rate
• Glycation End Products, Advanced (antagonists & inhibitors, blood)
• Humans
• Lysine (analogs & derivatives, antagonists & inhibitors, blood)
• Male
• Middle Aged
• Oxidative Stress (drug effects)
• Quinolines (therapeutic use)
• Renal Insufficiency, Chronic (blood, diet therapy, drug therapy, pathology)
• Triglycerides (blood)
• Vascular Stiffness (drug effects)